Alan K Burnett
Overview
Explore the profile of Alan K Burnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
9782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Copland M, Ariti C, Thomas I, Upton L, Sydenham M, Mehta P, et al.
Br J Haematol
. 2023 Nov;
204(3):871-876.
PMID: 38016651
Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC)...
2.
Mussai F, De Santo C, Cheng P, Thomas I, Ariti C, Upton L, et al.
Br J Haematol
. 2022 Nov;
200(5):573-578.
PMID: 36413792
The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is...
3.
Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, et al.
Leuk Lymphoma
. 2022 Oct;
64(1):250-252.
PMID: 36226777
No abstract available.
4.
Tazi Y, Arango-Ossa J, Zhou Y, Bernard E, Thomas I, Gilkes A, et al.
Nat Commun
. 2022 Aug;
13(1):4622.
PMID: 35941135
Clinical recommendations for Acute Myeloid Leukemia (AML) classification and risk-stratification remain heavily reliant on cytogenetic findings at diagnosis, which are present in <50% of patients. Using comprehensive molecular profiling data...
5.
Russell N, Hills R, Kjeldsen L, Clark R, Ali S, Cahalin P, et al.
Br J Haematol
. 2022 Apr;
198(3):528-534.
PMID: 35388465
The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK...
6.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2022 Jan;
13(1):2.
PMID: 34983928
No abstract available.
7.
Linch D, Hills R, Burnett A, Russell N, Gale R
Br J Haematol
. 2021 Dec;
196(6):1348-1352.
PMID: 34870324
Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2) -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2 and...
8.
Dillon R, Hills R, Burnett A, Russell N
Br J Haematol
. 2021 Nov;
196(5):e50-e52.
PMID: 34799856
No abstract available.
9.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2021 Oct;
12(1):6233.
PMID: 34716350
Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating...
10.
Russell N, Hills R, Thomas A, Thomas I, Kjeldsen L, Dennis M, et al.
Haematologica
. 2021 Oct;
107(7):1518-1527.
PMID: 34647442
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial...